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AU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:Scabies i a neglected tropical disea e (NTD) that caus s a significant health burden, par-
ticularly in disadvantaged communities and where there is overcrowding. There is emerging evi-
dence that ivermectin-based mass drug administration (MDA) can reduce the prevalence of
scabies in some settings, but evidence remains limited, and there are no formal guidelines to
inform control efforts. An informal World Health Organization (WHO) consultation was organized
to find agreement on strategies for global control. The consultation resulted in a framework for
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scabies control and recommendations for mapping of disease burden, delivery of interventions,
and establishing monitoring and evaluation. Key operational research priorities were identified.
This framework will allow countries to set control targets for scabies as part of national NTD stra-
tegic plans and develop control strategies using MDA for high-prevalence regions and outbreak
situations. As further evidence and experience are collected and strategies are refined over
time, formal guidelines can be developed. The control of scabies and the reduction of the health
burden of scabies and associated conditions will be vital to achieving the targets set in WHO
Roadmap for NTDs for 2021 to 2030 and the Sustainable Development Goals.
Introduction
In 2017, scabies was added to the portfolio of the World Health Organization (WHO) Depart-
ment of Control of Neglected Tropical Diseases (NTDs) because of the burden of scabies and
its complications, particularly in areas with limited access to healthcare and because of poten-
tial new public health control strategies. To find agreement on common strategies and identify
research priorities for a global control strategy, an informal WHO consultation meeting was
organized in 2019 [1]. This consultation occurred in the broader context of a new roadmap for
NTDs for the period of 2021 to 2030 [2]. Here, we propose a framework for scabies control
arising from the expert consultation, within the context of WHO NTD Roadmap. These rec-
ommendations represent the view of the expert group, based on current data, and, therefore,
the framework is a reasonable basis for piloting of activities, pending formal WHO guidelines.
Scabies is caused by the ectoparasite Sarcoptes scabiei var. hominis. Transmission generally
requires skin-to-skin contact, and zoonotic transmission does not occur. Common scabies
infestation typically involves a small number of mites. A hypersensitivity reaction to mites and
their products causes itch, which is frequently very severe, and skin lesions of variable severity.
Scabies is a strong risk factor for superficial bacterial skin infection (impetigo), which can
progress to severe bacterial infections, poststreptococcal glomerulonephritis, and possibly
acute rheumatic fever and chronic kidney disease [3].
Scabies occurs in all countries, but most cases occur in low-income and middle-income coun-
tries, where overcrowding increases transmission and access to effective treatment is often limited
[4]. Significant gaps remain in understanding the global epidemiology of scabies. Modeling studies
have estimated a global point prevalence of 100 to 200 million cases of scabies and 455 million
annual incident cases [5], but there are very few estimates based on surveys or surveillance. Epidem-
ics can occur in regions with high transmission and in settings of overcrowded living conditions.
Institutions, such as aged care facilities, schools, prisons, and hospitals, are common settings for out-
breaks, including in high-income settings that otherwise have a low prevalence of scabies [6].
Targeted programs for the public health control of scabies have been piloted in a limited
number of sites but have not been implemented at scale. There is strong emerging evidence
suggesting that mass drug administration (MDA) can markedly reduce the prevalence of sca-
bies. Effectiveness has been best demonstrated in high-prevalence, island settings [7,8]. There
is more limited evidence in non-island populations or lower prevalence contexts [9,10].
A framework for scabies control
The proposed framework for scabies control includes recommendations for (1) mapping of
disease burden; (2) delivery of interventions; and (3) establishing an appropriate monitoring
and evaluation framework (Fig 1).
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Fig 1. Overview of framework for scabies control. MDA, mass drug administration.
https://doi.org/10.1371/journal.pntd.0009661.g001
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Mapping the disease burden
Achieving a better understanding of the burden of scabies is impeded by the lack of a “field-
friendly” test for diagnosis. Definitive diagnosis is made by microscopic examination of skin
scrapings, which is insensitive and impractical in the field. Consensus diagnostic criteria devel-
oped by the International Alliance for the Control of Scabies (IACS) categorize diagnosis into
1 of 3 levels of certainty: confirmed scabies (which requires specialized equipment to directly
visualize the mite or its products), clinical scabies, and suspected scabies (which rely on clinical
signs and history features) [11]. The 2020 IACS criteria could be used as a standard to better
define the burden of scabies, as detailed below.
As a prelude to mapping, a desk-based review of routinely collected health data and previ-
ous surveys in the country might provide insight into whether scabies is a public health prob-
lem and identify likely areas of relatively high burden. Discussions with clinical and
managerial health staff are also recommended, as scabies cases are frequently not well captured
in routine data.
Two types of survey activities are recommended for different control strategy circum-
stances. First, rapid mapping, which aims to identify areas where scabies prevalence is likely to
be above the 10% threshold for recommending an MDA strategy (see “Control interventions”
section below), and second, detailed prevalence surveys, which aim to provide more accurate
and longitudinal estimates where these are needed. Community-based, house-to-house sam-
pling across all age groups is recommended as the most robust methodology for both. School-
based surveys might be a reasonable alternative where community sampling is not feasible, but
this approach requires operational research (Table 1). An implementation unit population of
approximately 100,000 to 150,000 people is considered appropriate for both mapping and
MDA interventions in most regions, providing a balance between accuracy, detail, and logisti-
cal factors, particularly cost.
For rapid mapping, diagnosis should be based on a modified, simplified version of the 2020
IACS criteria. A limited skin examination of exposed areas of the limbs for typical lesions of
scabies is recommended, conducted by trained primary healthcare workers [12,13].
Prevalence surveys are recommended to provide more detailed regional estimates of preva-
lence, to advocate for appropriate resources for control, and to monitor prevalence over time,
including to assess the impact of control interventions. The 2020 IACS criteria can be used for
diagnosis based on clinical assessment in most circumstances. Information about superficial
bacterial skin infection (impetigo and infected scabies) should also be collected during rapid
mapping and prevalence surveys.
Control interventions
Mass drug administration. Based on existing evidence, pilot control initiatives using
MDA are recommended in areas where community prevalence is 10% or higher. A total of 3
to 5 rounds of annual MDA are recommended. The recommended threshold for stopping
MDA after these rounds is a community prevalence of<2%. Alternatives strategies to MDA,
such as screen and treat (in which the population is screened by clinical assessment and treated
only if the exam is consistent with scabies), are likely to be more resource intensive and less
effective than MDA, although comparative studies are lacking.
The recommended regimen for MDA is 2 doses of oral ivermectin (200 μg/kg) given 7 to 14
days apart, using directly observed treatment wherever possible. Either weight- or height-
based dosing is appropriate. Weight-based dosing is more accurate, while height-based dosing
is more practical. Topical treatment is recommended for those for whom ivermectin MDA is
currently not approved (pregnant women, lactating mothers in the first week, and children
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weighing <15 kg or <90 cm height). Evaluation of the safety of ivermectin in these groups is a
research priority (Table 1) [14–16]. Permethrin 5% is the preferred topical treatment. Benzyl
benzoate can be used where permethrin is unavailable but may be less effective and cause
more adverse events. The recommended minimum coverage target is 80% of the total popula-
tion receiving 2 doses of treatment (either oral or topical).
Environmental measures (e.g., washing linen and clothing) are highly resource intensive
and unlikely to add significant benefit to MDA, and, therefore, are not recommended compo-
nents of a control strategy in low-resource settings. Water, sanitation, and hygiene (WASH)
interventions are not effective for scabies but can reduce secondary bacterial infection [17,18].
Control strategies below the MDA threshold. MDA is not recommended where the esti-
mated prevalence is <2%. Where the prevalence is between 2% and 10%, there are currently
Table 1. Priority research issues for scabies control.
Medications and safety
Effectiveness of single-dose ivermectin-based MDA strategy (compared to current 2-dose recommendation)
Safety of ivermectin in currently contraindicated groups (pregnant and breastfeeding women and children
weighing<15 kg or <90 cm in height)
Safety of permethrin in infants aged <2 months
Safety of coadministration of ivermectin with medications used in other MDA programs
Efficacy of moxidectin for the treatment and community control of scabies
Interventions
Prevalence thresholds for starting and stopping MDA
Optimal number of MDA rounds to achieve sustainable control
Effectiveness of MDA in diverse settings including non-island and urban settings
Effectiveness of control strategies when scabies prevalence is <10% (including targeted MDA, screen and treat,
and IDM); comparisons of effectiveness, cost, and feasibility should be made with community MDA
Integration of MDA regimens that use ivermectin for other NTDs to maximize the impact on scabies.
Effect of stopping ivermectin MDA for other NTDs on scabies transmission
Effectiveness of MDA for scabies outbreaks in various settings
Mapping, monitoring, and evaluation
Further validate the 2020 IACS criteria, rapid mapping criteria, and training programs for field assessment
Develop monitoring and evaluation methodologies, including sampling, diagnostic tools or needs, and frequency
of assessment
Define the relationship between scabies prevalence in schools and in communities
Define the relationship between scabies and impetigo in various settings, including the extent to which MDA for
scabies reduces the burden of impetigo
Evaluate different sampling strategies for scabies mapping, including cluster and geospatial sampling designs
Integration of monitoring and evaluation for scabies into existing systems for other diseases
Develop new diagnostic tools (e.g., point of care or rapid diagnostic tests) aligned with programmatic thresholds
Develop strategies to detect recurrence of scabies transmission after cessation of MDA
Monitor for development of resistance of mites to ivermectin and permethrin
Morbidity and costs
Determine the impact of scabies MDA on the complications of scabies, including skin and soft tissue infections,
invasive bacterial disease, glomerulonephritis, and rheumatic heart disease
Measure impact of scabies and associated impetigo on quality of life, including absenteeism from school and work
and broader social costs
Compare cost of scabies control program activities and health-related cost savings and cost-effectiveness of
control strategies
IACS, International Alliance for the Control of Scabies; IDM, intensified disease management; MDA, mass drug
administration; NTD, neglected tropical disease.
https://doi.org/10.1371/journal.pntd.0009661.t001
PLOS NEGLECTED TROPICAL DISEASES Scabies control framework
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0009661 September 2, 2021 5 / 9
no evidence-based recommendations for the choice of the most appropriate control strategy.
The optimal approach should be decided based on the local context and circumstances. Possi-
ble strategies include intensified disease management (IDM), screen and treat, or targeted
MDA of a high-risk subpopulation. Components of an effective approach might include
ensuring scabies treatments are available and affordable where they are needed and enhancing
clinical management of scabies in primary care (in particular, ensuring close contacts of an
infested patient are treated simultaneously with the patient). Active case finding with appropri-
ate referral or treatment, such as the approach used in screening programs for “skin NTDs,”
could be considered [19,20]. Suspected cases of crusted scabies (an uncommon, highly trans-
missible variant) should be identified and referred for specialized assessment and management
of the individual case and their environment. Additional considerations for control are sum-
marized in Table 2. Integration of these strategies into existing health systems and programs is
crucial for the success and sustainability of scabies control.
Control of scabies outbreaks. Ivermectin-based MDA has been effectively used for the
control of outbreaks in the community and in closed institutions [6,21]. Further research and
consensus are required to define the appropriate methods and thresholds for detecting and
declaring scabies outbreaks, the optimal strategy for outbreak control, and criteria for success-
ful control of a scabies outbreak, including when the interventions can be stopped.
Monitoring and evaluation
An impact assessment should be conducted after completing the planned 3 to 5 rounds, to
determine whether MDA should be stopped (i.e., if the prevalence is<2%) or continued lon-
ger. More frequent assessment will be required for operational research in initial pilot program
sites. Evaluation of impact should assess the burden of scabies, impetigo, and health-related
complications. It is also important to monitor for recrudescence of transmission after cessation
Table 2. Additional considerations for scabies control programs.
Implementation
Integrate where possible with programs for other NTDs and other health programs, including at stages of
mapping, implementation, and surveillance
Engage communities to promote inclusivity, ownership, and sustainability. Use and adapt engagement strategies
developed for other NTD programs
Develop and implement packages to train and upskill of health system staff and program managers regarding
scabies control issues
Refine existing training packages for assessment of scabies and impetigo for mapping, relevant for local
circumstances
Cost and access
Ensure that scabies management is included in national essential packages of care as part of Universal Health
Coverage
Cost might be a barrier to control because of the higher cost of 2-dose regimens and current absence of a drug
donation program
Improve access to low-cost ivermectin and permethrin. This will require local and global advocacy
Safety
There is widespread experience using ivermectin and permethrin. Both are considered safe and well-tolerated
treatments
Use existing frameworks for safety monitoring and reporting from other NTD programs
A prompt and appropriate response to adverse events is required to maintain confidence in programs
NTD, neglected tropical disease.
https://doi.org/10.1371/journal.pntd.0009661.t002
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of MDA [22]. Assessment of cost effectiveness and social impact will be valuable, particularly
for initial, pilot programs.
Epidemiologic data on scabies during the program can be collected through a hybrid
approach, including sentinel surveillance at selected sites. Methods for impact assessment and
surveillance at specific sites should follow the recommendations for prevalence surveys, as
described above. Process (e.g., coverage) and outcome (e.g., impact of treatment on preva-
lence) should be evaluated at some sites, and these should be linked when possible.
Routine collection, analysis, and reporting of data on scabies presentations at healthcare
facilities should be strengthened and supported. The results of monitoring and impact assess-
ments should be communicated to frontline workers and affected communities.
Scabies, Universal Health Coverage, and WHO NTD Roadmap
WHO NTD Roadmap for 2021 to 2030 was endorsed by the 73rd World Health Assembly in
November 2020. The roadmap sets global targets, milestones, and strategies to control and
eliminate NTDs, as well as crosscutting targets aligned with WHO’s Thirteenth General Pro-
gramme of Work, 2019–2023 and the Sustainable Development Goals [2,23]. For scabies and
other ectoparasites, the proposed targets are the following: (1) the number of countries having
incorporated scabies management in the Universal Health Coverage package of care (from 0
in 2020 to 50 in 2025 to all 194 by 2030); and (2) the number of countries using MDA in all
endemic districts (from 0 in 2020 to 6 in 2025 to 25 in 2030). The roadmap report notes the
critical actions to reach these targets for scabies control, including the development of guid-
ance for mapping and for the implementation of preventive chemotherapy. Opportunities to
integrate with other NTD programs where ivermectin is already used (onchocerciasis and lym-
phatic filariasis) are noted, as is the opportunity to integrate scabies control with approaches to
the control of skin NTDs [20,24].
Next steps
Although there are significant gaps in the evidence upon which to design a scabies control pro-
gram, there is now sufficient evidence to commence control activities, particularly in the high-
est prevalence settings. Countries that have identified scabies control as a public health priority
can use this framework as a basis for control programs, supported by WHO and organizations
such as the World Scabies Program [25]. The implementation of scabies control in these coun-
tries will serve as important pilot sites. Priority operational research questions (Table 1) should
be addressed alongside implementation, as discussed in detail elsewhere [1,3]. Both ivermectin
and permethrin are now included in WHO Model List of Essential Medicines for the treat-
ment of scabies, potentially facilitating prequalification of new manufacturers and suppliers of
generic treatments. Work is needed to increase affordable access to these treatments.
Conclusions
This framework for scabies control is an important step toward addressing an important,
unmet global health need. The framework will allow countries to set control targets for scabies
as part of national NTD strategic plans and facilitate the development of control strategies
using MDA for high-prevalence regions and outbreak situations. It will also assist researchers
and partners to tackle the key issues for scabies control. As operational research is completed
and pilot projects are scaled up, strategies should be refined and shared. Once sufficient data
are available, this framework could develop into formal guidelines to be reviewed through the
standard, rigorous WHO process. The successful control of scabies will be vital to achieving
the targets set in WHO NTD Roadmap and the Sustainable Development Goals.
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